Add Company
Join Now

Imugene Limited Revenue and Competitors

License our Company Data API

Sydney, AUS

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Imugene Limited's estimated annual revenue is currently $14.3M per year.(i)
  • Imugene Limited's estimated revenue per employee is $155,000

Employee Data

  • Imugene Limited has 92 Employees.(i)
  • Imugene Limited grew their employee count by 241% last year.

Imugene Limited's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$376.5M20734%N/AN/A
#2
$1.1M1183%N/AN/A
#3
$7.5M6120%$106.1MN/A
#4
$11.3M73N/AN/AN/A
#5
$18.6M12033%N/AN/A
#6
$20.3M12618%N/AN/A
#7
$1.7M5-44%N/AN/A
#8
$69.3M53338%N/AN/A
#9
$28.7M1855%N/AN/A
#10
$25M16155%N/AN/A
Add Company

What Is Imugene Limited?

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets. ASX: IMU

keywords:N/A

N/A

Total Funding

92

Number of Employees

$14.3M

Revenue (est)

241%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$26.7M9210%N/A
#2
$14.9M92-7%N/A
#3
$25.5M92-8%N/A
#4
$9.6M9256%N/A
#5
$20.2M9219%N/A